This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas N. Chase, MD; Anne C. Woods, MB, BS; George A. Glaubiger, MD, PhD

Arch Neurol. 1974;30(5):383-386.

Abstract
A single-blind crossover trial of a putative dopamine receptor stimulating agent, piribedil, was conducted in 16 patients with idiopathic parkinsonism. At maximum dose levels overall improvement in parkinsonian signs averaged 30%. Adverse effects included gastrointestinal disturbances, behavioral alterations, and dyskinesias, but were severe enough to require drug withdrawal in only one patient. The antiparkinsonian efficacy of levodopa together with a peripheral decarboxylase inhibitor, tested in 12 of these patients, was about twice that of piribedil. Levodopa treatment failures due to toxic effects other than dyskinesias responded well to piribedil. As expected of a dopamine receptor agonist, piribedil substantially reduced the central turnover of this monoamine as estimated by the probenecid loading test.

Author Affiliations
Bethesda, Md

From the Neurology Unit, National Institute of Mental Health, Bethesda, Md. Dr. Woods is now with the Children's Hospital of the District of Columbia.

Footnotes
Accepted for publication Dec 12, 1973.

Read in part before the Symposium International Trivastal, Monastir, Tunisia, Dec 1, 1972, and the Tenth International Congress of Neurology, Barcelona, Spain, Sept 13, 1973.

Reprint requests to Neurology Unit, NIH Clinical Center, 9000 Rockville Pike, Bethesda, MD 20014 (Dr. Chase).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Movement disorders of aged rats: reversal by dopamine receptor stimulation
Marshall and Berrios
Science 1979;206:477-479.
ABSTRACT  

Effects of a Dopamine Agonist Piribedil in Depressed Patients: Relationship of Pretreatment Homovanillic Acid to Antidepressant Response
Post et al.
Arch Gen Psychiatry 1978;35:609-615.
ABSTRACT  

Brain Dopamine Turnover and the Relief of Parkinsonism
Rinne et al.
Arch Neurol 1977;34:626-629.
ABSTRACT  

Five Years' Treatment of Parkinson's Disease with Levodopa: Therapeutic Results and Survival of 100 Patients
SWEET and McDOWELL
ANN INTERN MED 1975;83:456-463.
ABSTRACT